- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00215904
D-serine Adjuvant Treatment for Parkinson's Disease
The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine (~2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced dyskinesias.
D-serine will be used as add-on therapy to on-going medications received by Parkinson's Disease patients. The rational for this study stems from observations made in pervious clinical trials with schizophrenia patients, in which it was demonstrated that D-serine adjuvant treatment resulted in:1)improvement of parkinsonian side effects induced by antipsychotic drugs and 2) improvement of depression and negative (i.e apathy, blunted effects, anhedonia) symptoms which are similar to symptoms encountered in Parkinson's Disease.
The study will have a crossover design in accordance to which each patient will receive, in random order D-serine and placebo for a 6 weeks period each. Thus, any participant will have the opportunity to receive the experimental treatment.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91351
- Ezrath Nashim - Herzog Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- PD diagnosis
- ≥2 on UPDRS items 32,33
- receive treatment with L-dopa alone or in combination with other antiparkinsonian medications.
Exclusion Criteria:
- current or previous history of other neurological disorders
- unstable medical conditions
- renal pathology
- pregnant female patients excluded
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2
|
Two 6 weeks treatment arms.
One arm: adjuvant treatment with D-serine (~2g/day).
Second arm : adjuvant treatment with placebo (~2g/day).
|
Placebo Comparator: 1
|
Two 6 weeks treatment arms.
One arm: adjuvant treatment with D-serine (~2g/day).
Second arm : adjuvant treatment with placebo (~2g/day).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
UPDRS scores
Time Frame: 6 weeks
|
6 weeks
|
PANSS scores
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Uriel Heresco-Levy, Ezrath Nashim - Herzog Memorial Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Heresco1CTIL
- 20030312
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on D-serine (~2g/day)
-
Herzog HospitalCompleted
-
Ewha Womans UniversityUnknownKidney Failure, ChronicKorea, Republic of
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Allama Iqbal Open University IslamabadShifa International HospitalUnknownCritical Illness | Malnutrition; ProteinPakistan
-
Chinese University of Hong KongCompleted
-
NIZO Food ResearchIngredion IncorporatedCompletedFunctional ConstipationNetherlands
-
University of NottinghamActive, not recruitingSugar; Blood, HighUnited Kingdom
-
Thames Valley UniversityWembley Health Care centre, NHS, UK.; Monks Park Primary care centre, NHS UK.; Willesden Health centre, NHS, UK...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Maastricht University Medical CenterRaisio Nutrition Ltd.Completed
-
Nathan Kline Institute for Psychiatric ResearchNational Institute of Mental Health (NIMH)Completed